<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00048295</url>
  </required_header>
  <id_info>
    <org_study_id>ISIS 2302-CS21</org_study_id>
    <nct_id>NCT00048295</nct_id>
  </id_info>
  <brief_title>Alicaforsen (ISIS 2302) in Patients With Active Crohn’s Disease</brief_title>
  <official_title>ISIS 2302-CS21, Phase 3 Double-Masked, Placebo-Controlled Study of Alicaforsen (ISIS 2302), an Antisense Inhibitor of ICAM-1, for the Treatment of Patients With Active Crohn’s Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ionis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ionis Pharmaceuticals, Inc.</source>
  <brief_summary>
    <textblock>
      ISIS 2302 is an antisense oligonucleotide drug that reduces the production of a specific
      protein called intercellular adhesion molecule (ICAM-1), a substance that plays a significant
      role in the increase of inflammation. People with Crohn’s disease have been shown to
      over-produce ICAM-1 in their gut tissues. Alicaforsen works by blocking ICAM-1 messenger RNA,
      the “instruction” molecule that is required for the production of ICAM-1 protein. This trial
      will examine effects of alicaforsen delivered by 2-hour intravenous infusion over a four-week
      period, compared to a placebo. Patients may remain on stable background 5-ASA, antibiotic, or
      immunosuppressive drugs, and prednisone (or equivalent) at &lt;/= 30 mg per day.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>May 2002</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>150</enrollment>
  <condition>Crohn's Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alicaforsen</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Age &gt;/= 12 years

          2. Weight &gt;/= 36 kg

          3. CDAI score of 220 – 400

          4. Documentation of Crohn’s disease activity by endoscopy, biopsy or imaging in the last
             2 years

          5. No TNF-α inhibitor treatment for three months prior to first study drug infusion

        Exclusion Criteria

          1. Known severe, fixed, symptomatic stenosis of the small or large intestine with
             significant dilation

          2. Extensive external fistulization (&gt; 3 external fistulae which are expressible with
             gentle compression); colostomy or ileostomy

          3. Active infection, including infectious colitis, or infection with HIV, Hepatitis B or
             Hepatitis C

          4. Malignancy within 3 years or poorly controlled medical illness

          5. Requires intravenous heparin therapy or with a history of a bleeding problem
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Kortrijk</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roeselare</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hradic Kralove 2</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Olomouc</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Prague</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Usti nad Orlici</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Minden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Munster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Szczecin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.centerwatch.com</url>
    <description>Type &quot;ISIS 2302&quot; in search box</description>
  </link>
  <link>
    <url>http://www.acurian.com</url>
    <description>Type &quot;ISIS 2302&quot; in search box, then click on &quot;Crohn's Disease Alicaforsen Investigation&quot;</description>
  </link>
  <verification_date>April 2004</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 29, 2002</study_first_submitted>
  <study_first_submitted_qc>October 29, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2002</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alicaforsen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

